Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NNVC with free AI briefings, catalyst countdowns, and dilution alerts.

NNVC · NanoViricides, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar: financing pressure. About 2.7 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), an at-the-market (ATM) program filed Oct 21, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 months of cash or less, 51% sold new shares within three months and 73% were lower 60 trading days later (median -24%). How we know
$2.6M Cash on Hand
2.7mo Cash Runway
3.3% Short Interest
$6 Analyst Target (2)
Follow NNVC by email Get an email when NNVC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NNVC, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

NNVC holds $2.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.9M/quarter from operations, an estimated runway of 2.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 69 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NNVC files for a raise →

👥 Who Owns NNVC

Insiders 1.9% Institutions (51 holders) 9.3% Public and other holders 88.8%
HolderTypeShares% of sharesAs of
Vanguard Capital Management LLC Institution (13F) 919,313 3.60% 2026-09-30
Milton Boniuk
10% Owner before reverse split · +16,850 options
Insider 491,721 1.93% 2017-02-21
Geode Capital Management, LLC Institution (13F) 229,491 0.90% 2026-09-30
Blackrock Inc. Institution (13F) 158,753 0.62% 2026-09-30
Miller Financial Services LLC Institution (13F) 134,000 0.52% 2026-09-30
Vanguard Fiduciary Trust Co Institution (13F) 131,923 0.52% 2026-09-30
Susquehanna International Group, LLP Institution (13F) 126,350 0.50% 2026-09-30
Renaissance Technologies, LLC Institution (13F) 98,300 0.39% 2026-09-30
Creative Planning Institution (13F) 86,761 0.34% 2026-09-30
UBS Group AG Institution (13F) 70,397 0.28% 2026-09-30
Northern Trust Corporation Institution (13F) 64,168 0.25% 2026-09-30

Share count 25,525,000 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NNVC picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NNVC and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.